Cyclerion Therapeutics Inc (CYCN)

$1.48 -0.01 (-0.34%)
Market Cap 5.69M
Revenue (ttm) 2.00M
Net Income (ttm) -3.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -153.00%
Debt to Equity Ratio 0.00
Volume 34,872
Avg Vol 1,835,286
Day's Range N/A - N/A
Shares Out 3.93M
Stochastic %K 57%
Beta 0.94
Analysts Strong Buy
Price Target $8.00

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8778
Address:
245 First Street, Riverview II, 18th Floor, Cambridge, United States
StockTwitsGhost
StockTwitsGhost Mar. 17 at 8:58 PM
$CYCN CYCN Ownership Analysis — SEC Filings (Form 3, 4, 13D, 13G, 13F) Total Shares Outstanding: 3.925M TOTAL KNOWN CONCENTRATED OWNERSHIP ~2,020,261 shares = 50.4% Float is razor thin. 👀 INSIDERS (33.6%) Peter Hecht — 1,028,086 (26.2%) [incl. preferred] Regina Graul CEO — 100,303 (2.56%) [incl. RSUs + options] Errol DeSouza Chair — 80,000 (2.04%) [RSUs] Terrance McGuire — 41,010 (1.04%) Michael Higgins — 30,740 (0.78%) Steven Hyman — 20,000 (0.51%) [RSUs] Dina Katabi — 20,000 (0.51%) [RSUs] Rhonda Chicko CFO — 18 + 25,000 options INSTITUTIONS (15.8%) J. Wood Capital (13G) — 181,818 (4.63%) Tyndall Capital (13G) — 155,187 (3.95%) Siren LLC/Invus (13F) — 115,603 (2.95%) Geode Capital (13F) — 43,302 (1.10%) Two Sigma (13F) — 69,855 (1.78%) Vanguard (13F) — 23,490 (0.60%)
0 · Reply
StockTwitsGhost
StockTwitsGhost Mar. 17 at 6:35 PM
$CYCN There is a narrative circulating suggesting that CYCN’s low volume prevents longs from exiting positions. It is important to clarify that CYCN is a micro-cap, low-float security, with over 50% of shares held by insiders. Anyone familiar with CYCN would recognize that the “low volume trap” thesis is fundamentally flawed. I strongly question the origin of this narrative, which appears to be driven more by retail short interest—and potentially market-maker activity—than by any structural liquidity constraint. For context, trading data from November 8 to December 6, 2024, shows volumes ranging from as low as 11,700 shares to as high as 141 million shares. Such episodic spikes in volume are not anomalous and have recurred multiple times, most recently as of January 2026. Those genuinely concerned about liquidity constraints clearly do not appreciate the trading dynamics of CYCN, which exhibits substantial volatility and episodic volume surges that belie the notion of a low volume trap
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 17 at 5:06 PM
$CYCN Volume picking up and breaking above 100 and 50SMAs. Solid.
0 · Reply
OPTIONTURD
OPTIONTURD Mar. 17 at 5:04 PM
$CYCN Some mf-er just sold off 15,000 shares....thanks a lot...:-( 1.56 down to 1.44
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 17 at 3:05 PM
$CYCN About to start getting more expensive around here. Trying to add as much as possible while it's still at these levels.
0 · Reply
spinooch
spinooch Mar. 17 at 2:49 PM
$CYCN what does a guy have to do to get some volume around here?
1 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Mar. 17 at 2:28 PM
$CYCN shorts below...
0 · Reply
StockTwitsGhost
StockTwitsGhost Mar. 17 at 4:02 AM
$CYCN @skyrockets_Inc @skyhopes @Mr_Pithy @EZYME22 This is a sophisticated, filing-driven deep dive that highlights real, overlooked assets and near-term disclosure windows. The verifiable pieces (stake, pipeline progress, FDA/Akebia updates, 10-K delay) hold up strongly. The Series B revaluation thesis is the high-conviction “secret” that could drive explosive upside or fizzle if the MA signals are misinterpreted or the round terms disappoint. The $5 Million Company Hiding a $32 Million Secret in Plain Sight The completion of this analysis was timed to the Massachusetts annual filing deadline — and its passage today without a filing from either Cyclerion entity serves as unambiguous confirmation of the central thesis.​​​​​​​​​​​​​​​​ Cyclerion’s Massachusetts annual filing delay is one of the most significant forward-looking signals in this story — and when read against the complete public record, it points to a conclusion that the market has entirely missed. https://x.com/GainOf1/status/2033751440607613343
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 16 at 6:20 PM
$CYCN Playing with the numbers . Reverse merger scenario: -Cash + Shell value: ~10M -10% Tisento Stake Post Series B (risk-adjusted): ~25M -Praliciguat Akebia Deal (up to 450M milestones, risk-adjusted): ~20M -Olinciguat (not yet out-licensed): ~5M -Total RM value: ~60M -Shares outstanding: ~3.9M Total RM value per share: $15/share If Regina can pull off a successful reverse merger like above she will be a hero in my eyes :)
3 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 16 at 6:08 PM
$CYCN and the whole board screamed 'Pithy, is that you???'
1 · Reply
Latest News on CYCN
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Feb 17, 2026, 7:00 AM EST - 4 weeks ago

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript

Jan 6, 2026, 10:28 AM EST - 2 months ago

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Jan 5, 2026, 4:01 PM EST - 2 months ago

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

Sep 24, 2025, 12:53 PM EDT - 6 months ago

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Sep 23, 2025, 4:01 PM EDT - 6 months ago

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Dec 17, 2024, 8:08 AM EST - 1 year ago

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Cyclerion Appoints Regina Graul, Ph.D., as President

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Nov 30, 2023, 6:16 PM EST - 2 years ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 1, 2023, 4:00 PM EDT - 3 years ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cyclerion Announces Reverse Stock Split

May 15, 2023, 1:00 PM EDT - 3 years ago

Cyclerion Announces Reverse Stock Split

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Mar 22, 2023, 4:40 PM EDT - 3 years ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Nov 22, 2022, 7:00 AM EST - 3 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Aug 9, 2022, 4:00 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 28, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jul 26, 2022, 7:00 AM EDT - 3 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 28, 2022, 9:00 AM EDT - 4 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 4 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Jun 17, 2022, 11:27 AM EDT - 4 years ago

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 17, 2022, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 10, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

May 4, 2022, 4:01 PM EDT - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 24, 2022, 4:01 PM EST - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Feb 23, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Jan 26, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 11, 2021, 5:32 PM EST - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Nov 9, 2021, 4:01 PM EST - 4 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26, 2021, 4:29 PM EDT - 4 years ago

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Oct 20, 2021, 4:24 PM EDT - 4 years ago

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Sep 22, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Aug 23, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 29, 2021, 5:00 PM EDT - 5 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 22, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Jul 9, 2021, 6:14 AM EDT - 5 years ago

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 7:22 PM EDT - 5 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

Jun 4, 2021, 10:27 AM EDT - 5 years ago

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

AKBA

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Cyclerion Therapeutics Announces $18 Million Private Placement

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 27, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

May 25, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX SLGL

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Apr 27, 2021, 9:00 AM EDT - 5 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

StockTwitsGhost
StockTwitsGhost Mar. 17 at 8:58 PM
$CYCN CYCN Ownership Analysis — SEC Filings (Form 3, 4, 13D, 13G, 13F) Total Shares Outstanding: 3.925M TOTAL KNOWN CONCENTRATED OWNERSHIP ~2,020,261 shares = 50.4% Float is razor thin. 👀 INSIDERS (33.6%) Peter Hecht — 1,028,086 (26.2%) [incl. preferred] Regina Graul CEO — 100,303 (2.56%) [incl. RSUs + options] Errol DeSouza Chair — 80,000 (2.04%) [RSUs] Terrance McGuire — 41,010 (1.04%) Michael Higgins — 30,740 (0.78%) Steven Hyman — 20,000 (0.51%) [RSUs] Dina Katabi — 20,000 (0.51%) [RSUs] Rhonda Chicko CFO — 18 + 25,000 options INSTITUTIONS (15.8%) J. Wood Capital (13G) — 181,818 (4.63%) Tyndall Capital (13G) — 155,187 (3.95%) Siren LLC/Invus (13F) — 115,603 (2.95%) Geode Capital (13F) — 43,302 (1.10%) Two Sigma (13F) — 69,855 (1.78%) Vanguard (13F) — 23,490 (0.60%)
0 · Reply
StockTwitsGhost
StockTwitsGhost Mar. 17 at 6:35 PM
$CYCN There is a narrative circulating suggesting that CYCN’s low volume prevents longs from exiting positions. It is important to clarify that CYCN is a micro-cap, low-float security, with over 50% of shares held by insiders. Anyone familiar with CYCN would recognize that the “low volume trap” thesis is fundamentally flawed. I strongly question the origin of this narrative, which appears to be driven more by retail short interest—and potentially market-maker activity—than by any structural liquidity constraint. For context, trading data from November 8 to December 6, 2024, shows volumes ranging from as low as 11,700 shares to as high as 141 million shares. Such episodic spikes in volume are not anomalous and have recurred multiple times, most recently as of January 2026. Those genuinely concerned about liquidity constraints clearly do not appreciate the trading dynamics of CYCN, which exhibits substantial volatility and episodic volume surges that belie the notion of a low volume trap
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 17 at 5:06 PM
$CYCN Volume picking up and breaking above 100 and 50SMAs. Solid.
0 · Reply
OPTIONTURD
OPTIONTURD Mar. 17 at 5:04 PM
$CYCN Some mf-er just sold off 15,000 shares....thanks a lot...:-( 1.56 down to 1.44
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 17 at 3:05 PM
$CYCN About to start getting more expensive around here. Trying to add as much as possible while it's still at these levels.
0 · Reply
spinooch
spinooch Mar. 17 at 2:49 PM
$CYCN what does a guy have to do to get some volume around here?
1 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Mar. 17 at 2:28 PM
$CYCN shorts below...
0 · Reply
StockTwitsGhost
StockTwitsGhost Mar. 17 at 4:02 AM
$CYCN @skyrockets_Inc @skyhopes @Mr_Pithy @EZYME22 This is a sophisticated, filing-driven deep dive that highlights real, overlooked assets and near-term disclosure windows. The verifiable pieces (stake, pipeline progress, FDA/Akebia updates, 10-K delay) hold up strongly. The Series B revaluation thesis is the high-conviction “secret” that could drive explosive upside or fizzle if the MA signals are misinterpreted or the round terms disappoint. The $5 Million Company Hiding a $32 Million Secret in Plain Sight The completion of this analysis was timed to the Massachusetts annual filing deadline — and its passage today without a filing from either Cyclerion entity serves as unambiguous confirmation of the central thesis.​​​​​​​​​​​​​​​​ Cyclerion’s Massachusetts annual filing delay is one of the most significant forward-looking signals in this story — and when read against the complete public record, it points to a conclusion that the market has entirely missed. https://x.com/GainOf1/status/2033751440607613343
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 16 at 6:20 PM
$CYCN Playing with the numbers . Reverse merger scenario: -Cash + Shell value: ~10M -10% Tisento Stake Post Series B (risk-adjusted): ~25M -Praliciguat Akebia Deal (up to 450M milestones, risk-adjusted): ~20M -Olinciguat (not yet out-licensed): ~5M -Total RM value: ~60M -Shares outstanding: ~3.9M Total RM value per share: $15/share If Regina can pull off a successful reverse merger like above she will be a hero in my eyes :)
3 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 16 at 6:08 PM
$CYCN and the whole board screamed 'Pithy, is that you???'
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 16 at 3:28 PM
$CYCN Crammed right in the middle of the 50 and 100SMA. Ready to explode to the upside :)
0 · Reply
ShortTheStock
ShortTheStock Mar. 15 at 1:19 PM
$CYCN lmao , 2023?
1 · Reply
spinooch
spinooch Mar. 14 at 10:42 PM
$CYCN senor Pithy is bringing the heat this evening!
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 10:33 PM
$CYCN ANALYSTS’ PRICE TARGET 🎯 RANGE $8.08 TO $8.40. GOOD LUCK 🍀.
1 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 10:23 PM
$CYCN A licensing agreement with MIT as support for strategic relaunch. Good luck 🍀
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 10:07 PM
$CYCN COLLABORATION WITH MEDSTEER TO ENSURE SUCCESS OF CYC-126. GOOD LUCK 🍀
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 9:59 PM
$CYCN Positive pre-IND written feedback from FDA on CYC-126. Study start second half of 2026. Good luck 🍀 to all of us.
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 9:50 PM
$CYCN STRATEGIC SHIFT FORWARD - CYCLERION IS SELLING AND LICENSING LEGACY ASSETS TO FUND ITS STRATEGIC PIPELINE IN NEUROPSYCHIATRY. GOOD LUCK 🍀 TO INVESTORS.
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 9:39 PM
$CYCN FOCUSED ON BUILDING NEW PIPELINE FOR NEUROPSYCHIATRIC DISEASES W/ AN INDIVIDUALIZED THERAPY FOR TRD AS ITS FOUNDATIONAL PRODUCT CANDIDATE. GOOD LUCK 🍀
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 9:29 PM
$CYCN SNAPSHOT - Note one employee. Regina Graul, Ph.D. Keeps CYCN’s quarterly burn 🔥 to a minimum. Good luck 🍀
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 9:21 PM
$CYCN Deepti Sri, March 5, 2026 - Shares jumped 47%. Top 5 U.S gainers. Relaunch focus on therapies for neuropsychiatric conditions. Licensing agreement with MIT covering intellectual properties. TRD phase 2 trial in 2026. Good luck 🍀.
0 · Reply
Mr_Pithy
Mr_Pithy Mar. 14 at 9:12 PM
$CYCN BUY RATING FOR CYCN. Regina Graul, Ph.D. needs to act to get more than one analyst covering CYCN. Ms. Graul needs to hold informal chats, in-person conferences and fireside chats to build CYCN buyers, followers, watchers, etc. Do your job Ms. Graul. Good luck 🍀 to all of our honest investors.
0 · Reply